Pathogenesis of type II diabetes: Are there common causes for insulin resistance and secretion failure?

Experimental and Clinical Endocrinology and Diabetes

Volumn 107, Issue SUPPL. 2, 1999, Pages

  Häring, Hans Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Insulin receptor substrate; Insulin resistance; Insulin secretion; MODY; Peroxisome proliferator activated receptor; Type 2 diabetes

Indexed keywords

EID: 4243211898     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0029-1212145     Document Type: Article

References (12)

1. Almind K, Bjorbaek C, Vestergaard H, Hansen T, Echwald S, Pedersen O: Aminoacid polymorphisms of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet 342: 828-832: 1993
2. Araki et al: Characterization and regulation of the mouse insulin receptor substrate gene promoter. Mol Endocrinol 9: 1367-1379: 1995
3. Arner P: Obesity and insulin resistance in Swedish subjects. Diabet Med 13: S85-86: 1996
4. Balletshofer B, Rittig K, Enderle M, Volk A, Maerker E, Pfohl M, Rett K, Häring HU: Disturbed flow-associated brachial artery dilation in glucose-tolerant, insulin-resistant first-degree relatives of subjects with type 2 diabetes. Diabetologia 41: A313: 1997
5. Beck-Nielsen H, Groop LC: Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 94: 1714-1721: 1994
6. 12 myotubes: evidence for a PI3-kinase mediated effect. Diabetologia 40: 606-609: 1997
7. Berti L, Mosthaf L, Kroder G, Kellerer M, Tippmer S, Mushack J, Seffer E, Seedorf K, Häring HU: Glucose-induced translocation of protein kinase C isoforms in rat-1 fibroblasts is paralleled by inhibition of the insulin receptor tyrosine kinase. J Biol Chem 269: 3381-3386: 1994
8. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3-10: 1997
9. Bossenmaier B, Mosthaf L, Mischak H, Ullrich A, Häring HU: Protein kinase C isoforms beta 1 and beta 2 inhibit the tyrosine kinase activity of the insulin receptor. Diabetologia 40: 863-866: 1997
10. Burning JC, Michael MD, Winnay JN, Hayashi T, Hosch D, Acilli D, Goodyear LJ, Kahn CR: A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 2: 559-569: 1998
11. Buckingham RE, Al Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, Bond B, Turner NC, Clapham JC: Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 47: 1326-1334: 1998
12. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241: 270-274: 1997